Meta-analysis of the Effects of Denosumab and Romosozumab on Bone Mineral Density and Turnover Markers in Patients with Osteoporosis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Aug 2

PMID 37529613

Authors

Mingwei Hu

Yifan Zhang

Jianjun Guo

Cuicui Guo

Xue Yang

Xue Ma

Hao Xu

Shuai Xiang

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the alterations in bone mineral density and bone turnover marker concentrations following the administration of denosumab and romosozumab therapies in patients with osteoporosis.

Methods: PubMed was searched for studies published until January 28, 2023, that investigated the clinical efficacy and bone turnover marker changes of denosumab and romosozumab in the treatment of osteoporosis, with a minimum follow-up of 3 months in each study. Studies were screened, and data on changes in bone mineral density (BMD), P1NP, and TRACP-5b levels after treatment were extracted and included in the analysis.

Results: Six studies were analyzed. At 3 months after treatment, the romosozumab group showed greater changes in lumbar BMD and bone turnover markers. BMD of total hip and femoral neck was relatively delayed. Beginning at 6 to 12 months, romosozumab showed greater changes in bone mineral density and markers of bone turnover.

Conclusion: Both romosozumab and denosumab have antiosteoporotic effects, with greater effects on BMD and bone turnover markers observed within 12 months of romosozumab treatment.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier CRD42023395034.

Citing Articles

A framework of biomarkers for skeletal aging: a consensus statement by the Aging Biomarker Consortium.

Suo J, Gan Y, Xie Y, Xu S, Wang J, Chen D Life Med. 2025; 2(6):lnad045.

PMID: 39872060 PMC: 11748998. DOI: 10.1093/lifemedi/lnad045.

Treatment patterns and factors associated with discontinuation of monoclonal antibodies.

Alkaabi M, Rabbani S, Rao P, Mohamedelhassan M SAGE Open Med. 2024; 12:20503121241271817.

PMID: 39165864 PMC: 11334246. DOI: 10.1177/20503121241271817.

Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials.

Kobayashi T, Hara M, Shimanoe C, Morimoto T, Masaaki M, Ito K J Bone Miner Metab. 2024; 42(5):492-502.

PMID: 38977437 DOI: 10.1007/s00774-024-01531-5.

Protocol for preliminary, multicenteric validation of "PoCOsteo device": A point of care tool for proteomic and genomic study of osteoporosis.

Razi F, Ostovar A, Fahimfar N, Amoli M, Fana S, Dimai H Biol Methods Protoc. 2024; 9(1):bpae006.

PMID: 38559752 PMC: 10978377. DOI: 10.1093/biomethods/bpae006.

Sacroplasty for Sacral Insufficiency Fractures: Narrative Literature Review on Patient Selection, Technical Approaches, and Outcomes.

Singh M, Balmaceno-Criss M, Knebel A, Kuharski M, Sakr I, Daher M J Clin Med. 2024; 13(4).

PMID: 38398413 PMC: 10889545. DOI: 10.3390/jcm13041101.

References

Padhi D, Allison M, Kivitz A, Gutierrez M, Stouch B, Wang C . Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2013; 54(2):168-78. DOI: 10.1002/jcph.239. View

Semenov M, Tamai K, He X . SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280(29):26770-5. DOI: 10.1074/jbc.M504308200. View

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

Mochizuki T, Yano K, Ikari K, Okazaki K . Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study. Osteoporos Sarcopenia. 2021; 7(3):110-114. PMC: 8486617. DOI: 10.1016/j.afos.2021.08.001. View

Padhi D, Jang G, Stouch B, Fang L, Posvar E . Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2010; 26(1):19-26. DOI: 10.1002/jbmr.173. View

Kostenuik P . Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005; 5(6):618-25. DOI: 10.1016/j.coph.2005.06.005. View

van Bezooijen R, Roelen B, Visser A, van der Wee-Pals L, de Wilt E, Karperien M . Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199(6):805-14. PMC: 2212719. DOI: 10.1084/jem.20031454. View

Ominsky M, Boyce R, Li X, Ke H . Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2016; 96:63-75. DOI: 10.1016/j.bone.2016.10.019. View

Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y . Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021; 11(1):11801. PMC: 8175428. DOI: 10.1038/s41598-021-91248-6. View

10.

Lewiecki E, Blicharski T, Goemaere S, Lippuner K, Meisner P, Miller P . A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018; 103(9):3183-3193. DOI: 10.1210/jc.2017-02163. View

11.

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

12.

Fixen C, Tunoa J . Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk. Curr Osteoporos Rep. 2021; 19(1):15-22. DOI: 10.1007/s11914-020-00652-w. View

13.

Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23):6267-76. PMC: 291840. DOI: 10.1093/emboj/cdg599. View

14.

McClung M, Grauer A, Boonen S, Bolognese M, Brown J, Diez-Perez A . Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20. DOI: 10.1056/NEJMoa1305224. View

15.

Gregson C, Armstrong D, Bowden J, Cooper C, Edwards J, Gittoes N . UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022; 17(1):58. PMC: 8979902. DOI: 10.1007/s11657-022-01061-5. View

16.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

17.

Kearns A, Khosla S, Kostenuik P . Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2007; 29(2):155-92. PMC: 2528846. DOI: 10.1210/er.2007-0014. View

18.

Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9. View

19.

Holdsworth G, Roberts S, Ke H . Novel actions of sclerostin on bone. J Mol Endocrinol. 2018; 62(2):R167-R185. DOI: 10.1530/JME-18-0176. View

20.

Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T . Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol. 2022; 33(1):96-103. DOI: 10.1093/mr/roac014. View